420 with CNW – Cannabis Could Prevent Chronic Traumatic Encephalopathy, Researchers Reveal

February 8, 2019 16:20:57

Many athletes, such as footballers, commit suicide or die as a result of the brain trauma caused while they engage in contact sports. Chronic traumatic endephalopathy (CTE), a degenerative neurological condition, is one such brain trauma disease that conventional medicine has found so hard to prevent or treat partly because the condition can only be diagnosed posthumously. Now a number of scientists and researchers are suggesting that cannabis may help to prevent or alleviate the symptoms of this disease whose victims are mainly athletes (particularly footballers).

One study conducted in Israel found that the use of cannabis improved blood flow to the brain and prevented brain tissues from dying. While this study was conducted on rats and mice with head trauma, it brings hope for a solution to a problem from which 99 percent of all dead NFL players suffered, researchers say.

Another study conducted in the U.S. concluded that cannabis possesses neuro-protective properties because of the antioxidants it contains. In fact, Kyle Turley, a retired NFL player, uses cannabis to treat the traumatic brain injury he suffers from resulting from his days as a player. Turley was also a friend of another NFL player, Junior Seau, who fatally shot himself in 2012. Brain specialists who examined samples of Seau’s brain found that his suicidal tendency was due to CTE.

Apart from causing people to be suicidal, CTE causes depression, aggression, confusion, dementia and mood swings.

Turley is now an avid advocate for the use of cannabis to treat neurological conditions, especially among athletes.

His mission isn’t farfetched because a number of companies have been developing cannabis-based remedies for different neurological conditions. For example, KannaLife Sciences is developing a synthetic cannabis pill that is intended to prevent CTE in athletes. The company also makes other CBD-based remedies.

Another company, GW Pharmaceuticals, has already obtained FDA approval for Epidiolex, a CBD-based drug that can treat two forms of rare pediatric epilepsy. Epilepsy is a neurological condition, just like CTE. Epidiolex has already proved to be effective for some of the kids with the forms of epilepsy for which it was developed.

It should be noted that treating brain injury isn’t achieved by CBD alone. A study whose findings were published in The American Surgeon showed that patients who suffered brain injuries and tested positive for THC suffered fewer fatalities than those who didn’t test positive for THC.

Such findings provide good news to Green Hygienics Holdings Inc. (OTCQB: GRYN) and other players in the cannabis industry like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) because it offers a possible solution to a problem (CTE) that could be affecting millions of athletes.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office